Rights and permissions
About this article
Cite this article
French authority revises advice on rifampicin/pyrazinamide therapy. React. Wkly. 1019, 2 (2004). https://doi.org/10.2165/00128415-200410190-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-200410190-00001